Open access
Sep 2026
SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney
Abstract Sodium–glucose transport protein 2 inhibitors (SGLT2i), initially developed as antidiabetic agents and now established as foundational therapies for heart failure, have also shown antihypertensive effects in clinical trials involving patients with diabetes and heart failure. However, the underlying mechanisms...
Zhi-Tong Zhou, Wei-Jian Hang, Rui Zhao et al.
· Bioscience Reports · 0 citations